US 9562855

I'll search for the specific patent and check for any CAFC 2026 docket activity.

Let me dig deeper for the specific claims and any litigation or CAFC activity involving this exact patent.

Let me try to retrieve the exact claim language and confirm no litigation/docket activity.

US Patent 9,562,855 — Analyst Summary

Search scope note: I searched for the literal identifier US 9,562,855 / US9562855B1 (application 13/458,650) and cross-checked USPTO/Google Patents/FreePatentsOnline records plus Federal Circuit 2026 docket material. I did not find any CAFC 2026 docket entry, district-court case, IPR, or PTAB proceeding naming this patent. The litigation hits my queries surfaced (e.g., Headwater Research v. Verizon, Contour IP Holding v. GoPro, Extremity Medical v. Nextremity, a "9,562,785" RideCo/Via case) concern different patent numbers and are not this patent. Accordingly, I report no confirmed docket activity — which is materially different from confirming that none exists.

Bibliographic data (from the patent front page / Google Patents)

Note the distinguishing detail from the search results: this patent says it is a continuation-in-part (CIP) of 12/630,069; its sibling/related patent US 9,678,005 B1 (Yoon, issued Jun. 13, 2017) is a continuation of this '855 patent. Do not conflate the two.

Abstract (as printed)

Microfluidic methods and systems for detecting levels of microorganisms via Mie forward light scattering. The systems and methods of the present invention can be customized so as to optionally maximize scatter from the particle immunoagglutination and minimize that of the sample matrix, e.g., via selection of parameters particle diameter d, wavelength of incident λ, and/or scatter angle θ. Methods feature providing beads conjugated with an antibody specific for the microorganism, mixing beads with a sample to form a first mixture; providing a control mixture; irradiating the mixtures with incident light; detecting forward light scattering scattered by the first mixture at a first angle with respect to the incident light and forward scattered light scattered by the control the same first angle with respect to the incident light; determining I and I₀ from the light scattering; comparing I with I₀; and determining a level of the microorganism.

Plain-language overview of the claims

Caveat on precision: My sources retrieved the specification's "Summary" language and the claim count (3 claims) but not the verbatim granted claim text. The following describes the claim substance as reflected in the Summary and figures; exact wording/scope should be verified against the issued claims. Treat this as a faithful description, not a certified claim transcription.

The issued patent contains 3 claims. Based on the Summary and the figures, the invention covers two statutory classes:

1. A method of detecting a level of a microorganism (independent). In plain terms:

   • Provide a first bead suspension of microparticle beads conjugated with an antibody specific for a target microorganism (e.g., ~920 nm carboxylated polystyrene beads).
   • Mix beads with a portion of the sample → first mixture; provide a control (second) mixture.
   • Load both onto one slide/test chip (two channels or two wells) and irradiate with incident light — either both at once or without moving the slide between readings (the patent defines "simultaneous" as reading both from a single chip, not necessarily at the identical instant).
   • Detect forward-scattered light (Mie scattering) from the test mixture at a first angle and from the control at the same angle — recited as a particular angle between about 30° and 60° (spec examples emphasize ~44–46°, e.g. 45°).
   • Compute I (test) and I₀ (control), compare them (ratio I/I₀ or difference I−I₀), and convert to a level of microorganism (e.g., CFU/mL).

2. A system (independent) for the same detection, i.e., the handheld device counterpart: a housing with a testing cavity, an insertable test slide with first and second channels/test regions, a light device (single laser diode with beam splitter, or two parallel laser diodes, ~650 nm) that irradiates both test regions, and a light detection component (avalanche photodiode) fixed at the same detection angle (e.g., 45°) for both regions. The description notes a differential op-amp circuit, 24-bit ADC, microprocessor, and LCD display, with detection components optionally mounted in interchangeable cartridges at fixed angles.

3. The third claim is most likely a dependent claim narrowing one of the above (e.g., the angle value, bead size/composition, wavelength, or the control-mixture makeup), but I cannot confirm its exact scope without the printed claim text.

Customization concept pervading the claims/spec: wavelength λ, particle diameter d, and detection angle θ are chosen together (via Mie theory) so that scattered intensity from agglutinated (triplet) beads exceeds both unbound beads and the sample matrix at the chosen angle — the spec gives an example where matrix peaks ~38°, unbound singlets ~52°, and agglutinates ~46°, so ~45° is selected.

Bottom line

• US 9,562,855 is a granted, currently active (reinstated) patent to the University of Arizona (Yoon & You), a CIP of a 2009 application, with term extended to 2033-05-23.
• I found no CAFC 2026 docket or litigation involving this exact number. If you need a definitive litigation/PTAB check, that should be run against a dedicated database (PACER, CourtListener RECAP, PTAB API) because general web search is not authoritative for docket completeness.
• Uncertainty flag: I could not retrieve the verbatim text of the 3 issued claims; my claim overview is reconstructed from the specification's Summary and figures and should be verified against the official patent document.

I'll research litigation involving US Patent 9,562,855. Let me search across patent litigation databases.

Let me search more targeted sources for litigation records.

Litigation Search: US Patent 9,562,855

Result: No litigation involving US Patent 9,562,855 was found.

I searched for the specific patent number (9,562,855 / 9562855) across general web sources and litigation-oriented results. No lawsuits, complaints, dockets, PTAB proceedings, or other contested matters were located that involve this patent specifically.

What I found instead (and why I'm flagging it)

• The patent itself (U.S. 9,562,855 B1, "Devices and methods for detection of microorganisms via MIE scattering," inventors Jeong-Yeol Yoon and David Jinsoo You, assignee The Arizona Board of Regents on behalf of the University of Arizona, granted Feb. 7, 2017, application 13/458,650 filed Apr. 27, 2012, priority Dec. 3, 2009). Google Patents shows its status as "Active – Reinstated," adjusted expiration 2033-05-23. No litigation or adversarial events are listed on its face.
• False-positive traps. My search returned documents referencing similar but different numbers — e.g., U.S. 9,549,285 (Ortiz & Associates Consulting cases), U.S. 11,245,855, and payroll/accounting entries "9562855." Per your instruction I did not conflate these with the target patent. They are not related to US 9,562,855.
• Related-family activity exists, but not against '855. The '855 is a continuation-in-part in a family that includes U.S. 9,678,005. I did not find any assertion of the '005 or '855 either. The Arizona Board of Regents litigation and TTAB matters I surfaced (e.g., trademark cases and employment/IP disputes) are not patent infringement suits on '855.

Important caveats / limitations

• This result reflects the sources I could reach with web search. It is not a substitute for a complete PACER, Docket Navigator, Lex Machina, or Unified Patents portal query.
• I could not complete a direct query of the Unified Patents litigation portal (https://portal.unifiedpatents.com/litigation/caselist) or PACER within the constraints here, so there is a residual risk of an unreported or very recent filing.
• The patent's owner (a public university) has no publicly surfaced enforcement campaign on this patent that I could identify.

Recommended verification steps

To confirm the negative finding, I would recommend running the patent number directly in:

• Unified Patents litigation portal — search "9562855"
• PACER / CourtListener RECAP — docket search for "9,562,855"
• Docket Navigator or Lex Machina — patent-level litigation report
• USPTO PTAB — search for IPR/PGR on 9,562,855 (none found)

Bottom line: If asked to state the litigation history of US 9,562,855, the accurate answer is that no known litigation involves this patent based on the searches performed — I found nothing, and I will not attribute cases involving similar-numbered patents to it.

I'll verify the structured ODP signal against public PTAB/CAFC sources before writing up the (likely null) result.

Let me run a few more confirmatory checks against PTAB-specific and docket-specific sources.

Proceedings overview

Total on file: 0 AIA trial proceedings. The USPTO Open Data Portal (ODP) AIA-trial dataset returns no IPR, PGR, CBM, or derivation proceeding naming U.S. Patent No. 9,562,855 / application 13/458,650 as of the most recent ingest — i.e., 0 active, 0 claims-invalidated, 0 claims-sustained, 0 settled, 0 institution-denied. The bottom-line defensive posture is therefore "no PTAB record either way": the patent's three issued claims have not been tested, narrowed, or canceled at the Board, so a defendant has no ready-made invalidity judgment or estoppel weapon to cite — and equally, the patent owner has no IPR victory to brandish. The patent remains intact and presumptively valid, active (reinstated) with an adjusted expiration of 2033-05-23.

Because the structured ODP list is the canonical source and it is empty, the per-proceeding sections below have no entries to populate. I explain the verification steps and the two material caveats instead.

No proceedings to report

There is no ### IPR20XX-XXXXX — {Petitioner} v. {Patent Owner} block to write. Writing one would require inventing a proceeding number, petitioner, panel, and disposition — all of which the task instructions forbid. I found no such proceeding in the ODP data, and no public source surfaced one (details below).

What I checked, and what came back clean

⚠️ Search-noise disclaimer (important — do not conflate)

My queries surfaced several unrelated patents whose numbers merely end in or contain "855," and these are not US 9,562,855:

• U.S. 7,263,855 — cargo-container patent, the subject of IPR2022-00292 (that proceeding's FWD is about conception/corroboration, not Mie scattering).
• U.S. 8,578,285 — Cyandia, the subject of IPR2024-01495 (SAP America).
• "Eko '855" / "DeMiglio '855" — coffee-filter patent litigated in EKO Brands LLC v. Adrian Rivera Maynez Enterprises.
• A RideCo/Via "9,562,785" matter.

None of these involve US 9,562,855, Yoon, You, or the University of Arizona. Treat all of them as false positives.

Strategic summary

Claim status of 9,562,855: all 3 issued claims (1 independent method claim, 1 independent system claim, plus a dependent claim) are UNTESTED at the PTAB. Nothing is canceled; nothing has been sustained in a Board proceeding; no claim has been narrowed by a certificate. The patent is presumptively valid as issued and enforceable through its adjusted expiration of 2033-05-23. Contrast this with the front-page record, which shows only ordinary prosecution events (filing 2012-04-27, grant 2017-02-07, 1,267 days of PTA, reassignment to The Arizona Board of Regents on behalf of the University of Arizona) — no post-grant trail.

Estoppel landscape: § 315(e)(2) estoppel is not triggered, because it attaches only to a petitioner that obtains an instituted IPR/FWD. With no instituted proceeding, no party is estopped, and every § 102/§ 103 ground based on patents and printed publications remains fully available to a defendant in district court or the ITC. Conversely, the patent owner has no IPR-tested validity finding to point to. The practical asymmetry: the patent owner cannot say "the Board already upheld these claims," and the defendant cannot say "the Board already killed them."

Pattern signals: none observable. There is no serial-petitioner pattern, no defensive aggregator (e.g., Unified Patents) in any chain, and no Federal Circuit appeal arising from a PTAB decision on this patent. The more notable signal is the absence itself: this is a 2012-filed/food-safety diagnostic patent from a university licensor, and there is no public evidence of assertion activity that would normally attract a defensive IPR. Well-asserted patents eventually draw petitions; this one has not — consistent with a patent that is not currently being litigated in a way that has generated a public docket.

Cross-reference flag: the earlier-generated "Patent summary" section reported "no confirmed docket activity" via general web search. This task's structured ODP block independently corroborates that for AIA trials. The two are consistent; no contradiction to flag.

Recommended next steps

If you are a defendant being asserted against on 9,562,855:

1. You can file an IPR/PGR without any § 315(e) bar from a prior petitioner, since none exists. Nothing is off the table. If the asserted theory rests on the method claim (antibody-conjugated ~920 nm beads + same-angle Mie detection of test vs. control), the customization disclosure (λ, d, θ selection via Mie theory; matrix ~38° vs. singlet ~52° vs. triplet ~46°) gives you a specification-defined target for § 103 combinations of known immunoagglutination-scattering assays.
2. Do your own prior-art search; do not rely on the PTAB record. There is no FWD, no institution decision, and no petition to mine for art or claim construction. Search the family too: the CIP parent US 12/630,069 (filed 2009-12-03) and the sibling US 9,678,005 B1 (Yoon, 2017-06-13) may carry prosecution-history estoppel or prior-art admissions worth importing. Note the priority chain carefully — a CIP can only claim the earlier date for subject matter disclosed in the parent, so the effective filing date of individual claims is a live § 102/§ 103 attack surface.
3. Verify the null result in the authoritative databases before you rely on it. My checks were: (a) the USPTO ODP AIA-trial ingest provided in this prompt, and (b) targeted web searches. Web search is not authoritative for docket completeness. Before committing to a defense strategy, run the patent number directly against PTAB E2E (https://ptab.uspto.gov) and the USPTO ODP / PTAB API, and separately check PACER / CourtListener RECAP for district-court and CAFC dockets.
4. Cover the non-AIA bases. The ODP AIA-trial dataset does not cover ex parte reexamination or reissue. I found no evidence of a reexamination or reissue of this patent, but I could not confirm the absence definitively within this search; a direct check of the patent's Patent Center "Transaction History" (and the reexam certificate field) is the clean way to rule it out. An unnoticed ex parte reexam that canceled or narrowed claims would materially change the defensive picture.

Bottom line for the file: US 9,562,855 has no AIA trial history — no IPR, no PGR, no CBM, no settlement, no FWD, no PTAB appeal. Recommend a direct PTAB E2E / ODP-API confirmation plus a reexam-transaction check before treating "no PTAB activity" as final, since the absence of any post-grant challenge is itself the key datum a defendant needs.

I'll research the assignment record for US 9,562,855 / application 13/458,650.

Let me dig into the specific assignment records and the related patent family.

Ownership-chain analysis — US 9,562,855 B1

Evidence-availability flag (read first). I was not able to query the USPTO Assignment Center directly from this environment, and my web-search passes did not surface the page-format assignment records (reel/frame, correspondent) for this patent. Everything below is grounded in (a) the authoritative full patent text supplied in the prompt and (b) the Google Patents "Legal Events" mirror of the USPTO assignment record. Where I could not obtain a field (reel/frame, correspondent, execution date), I say so rather than inventing it. If the reel/frame is load-bearing for a filing, it must be pulled live from https://assignmentcenter.uspto.gov/ (search patent 9562855) or the legacy interface https://assignment.uspto.gov/patent/index.html.

Inventors

Unusual-pattern check: Nothing in the record shows inventors departing the assignee within 12 months of filing. To the contrary, both inventors executed an assignment in favor of the university roughly 4.5 years after filing and two months before issuance (recorded 2016-12-12), which is the opposite of a "departure/fire-sale" signature. No inventor-side transfer to a third party was found. Note the assignee/assignor name asymmetry flagged below.

Original assignee

• Entity named on the issued patent / current owner: The Arizona Board of Regents on behalf of the University of Arizona (Google Patents' front-page "current assignee" field renders this as "Arizona's Public Universities").
• Primary line of business: Public university governance board holding title to University of Arizona intellectual property; the underlying enterprise is a public research university (Tucson, AZ).
• Product embodying the claims: I found no evidence of a commercial product. The specification describes a hand-held optical immunoassay prototype built from a 3D-printed ABS casing, laser diode modules, APDs, and an Arduino-class microcontroller, validated in academic lab studies on lettuce and chicken-package water. This is university research apparatus, not a shipped commercial product.
• Current status: Operating (public institution; not acquired, dissolved, or in bankruptcy). No bankruptcy, merger, or fire-sale event appears in the chain.

Contradiction/uncertainty to flag: The filing record lists the applicant/filer as "Arizona's Public Universities," while the 2016-12-12 recorded assignment names the assignee as "THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA." These almost certainly denote the same institution under two naming conventions, but the exchanged names on the record do not literally match, and I am flagging that as a data-quality issue rather than resolving it silently.

Related-family note (do not conflate): This patent is a continuation-in-part of US 12/630,069 (filed 2009-12-03) and has a child, US 9,678,005 B1 (filed/priority-linked 2012-10-04). Any ownership query should be run for 9,678,005 separately; a clean chain on '855 does not automatically establish the '005 chain.

Assignment timeline

The Assignment Center / Google Patents Legal Events record for this patent shows a single post-filing assignment entry. I could not retrieve the reel/frame or correspondent from the sources available; those fields are shown as [not retrieved].

• Execution date [not retrieved] / recorded 2016-12-12 — Reel [not retrieved]/[not retrieved]
  • Conveyance: Assignment of assignors' interest (Google Patents labels the event "reassignment"; the assignment document itself is described as "ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)")
  • Assignor: YOON, JEONG-YEOL; YOU, DAVID JINSOO
  • Assignee: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
  • Correspondent: [not retrieved] — I could not confirm the recording attorney/firm from the sources I could reach. I therefore make no repeat-correspondent finding for this chain.
  • Context: Confirmatory / perfecting assignment routing individual-inventor title to the university pre-issuance — not an arm's-length acquisition, fire-sale, or transfer-to-asserter. It was recorded 2016-12-12, approximately two months before the 2017-02-07 grant.

Caveat: Because I could not query the Assignment Center live, I cannot rule out an earlier or subsequent recorded instrument that the mirror did not display (e.g., a separate pre-filing assignment from the 2012 filing, or a re-recording correcting it). The 2016-12-12 entry is the only one visible in my sources; treat "single recorded assignment" as what the mirror shows, not as a certified complete-chain statement.

Timeline diagram

timeline
    title Ownership of US 9562855
    2009 : Priority application 12/630,069 filed
         : CIP parent to this patent
    2012 : Application 13/458,650 filed
         : Filed by Arizona's Public Universities
    2016 : Inventors assign title to university
         : Recorded 2016-12-12
    2017 : Patent 9562855 B1 issued Feb 7
         : Assignee Arizona Board of Regents

NPE / troll-pattern signals

Cross-reference results: Google Patents Legal Events is my only confirmed mirror; search passes did not return the patent in RPX/Unified assertion directories, and hits for "9,562,855" in litigation material resolved to different patents (e.g., a CAO/GE heat-sink '855 patent and an unrelated Texas payroll line item) — not US 9,562,855 (Yoon).

Verdict

Insufficient data — with a strong non-NPE tilt.

Justification: The only recorded instrument in my sources is the 2016-12-12 confirmatory assignment from inventors Yoon and You to The Arizona Board of Regents on behalf of the University of Arizona, which is exactly the category the rubric defines as "only the original assignment." The chain terminates at the original, non-asserting institutional owner; there is no LLC transferee, no known asserter, no cascading transfer, no pre-litigation transfer, and no defensive-aggregator acquisition, so zero of the eight NPE signals are "present." The residual uncertainty is evidentiary, not substantive: I could not pull the reel/frame, the correspondent, or rule out an unmirrored record because I could not query the Assignment Center live.

Verify at: https://assignmentcenter.uspto.gov/ (search "9562855" or application "13/458,650") and legacy https://assignment.uspto.gov/patent/index.html — specifically request the full reel/frame list and the correspondent of record for the 2016-12-12 filing, which is the one field that would let a recurrence check (Signal 3) be run.

Standing caveats carried forward from the prior sections: (1) the verbatim text of the 3 issued claims was not recovered earlier and remains unverified; (2) the front page shows 1,267 days of PTA with adjusted expiration 2033-05-23; (3) this is a CIP of 12/630,069 with a separate child patent 9,678,005 — do not treat ownership of one as proof of ownership of the other without running the second search.

I'll research the specific prior-art references cited in US 9,562,855. Let me run targeted searches.

Let me get the complete "References Cited" list from the patent and details on each cited reference.

I have partial citations. Let me retrieve the full "References Cited" list from the patent front page.

US 9,562,855 B1 — Prior-Art Identification Report

0. Scope, method, and a disclosed limitation

I attempted to pull the complete "References Cited" block from the front page of US 9,562,855 (via Google Patents, FreePatentsOnline, Justia and the patentimages PDF). My searches confirmed several entries but my retrieval was cut off before I could enumerate the entire list verbatim. Treat the list below as confirmed-but-possibly-incomplete. Everything I did not personally see printed on the patent face or a faithful mirror of it is flagged as unverified. I did not find any ID that I can only report by assumption.

Target confirmation (literal ID, not auto-corrected): The searches returned US 9,562,855 B1 exactly — Devices and methods for detection of microorganisms via MIE scattering, Yoon & You, Arizona Board of Regents, filed 2012-04-27, granted 2017-02-07. Search results also surfaced look‑alike numbers that I am excluding and flagging so they are not conflated: US 9,562,785 (RideCo/Via), US 9,573,885 B2 (Pelletier), US 9,678,005 B1 (the '855 continuation, same inventors), and US 9,744,088 (IPR2019-00035). None of those is the target.

Important correction to the earlier generated section: The granted patent has 3 claims, all method claims — Claim 1 is the sole independent claim; Claims 2 and 3 depend from Claim 1. (Justia reproduces the issued text.) The earlier summary predicted an independent system claim; that prediction is wrong for the granted claims — no system claim issued. The system/apparatus subject matter survives only as specification disclosure (FIGS. 5–19), not as claim scope. This is a material contradiction and I flag it explicitly per the operating rules.

1. The actual granted claims (for the § 102 mapping)

Claim 1 (independent – method): steps (e)–(i), inter alia —

• (e) a system with (i) housing + testing cavity; (ii) insertable test slide with first and second channels that share a single inlet; a first lyophilized portion of antibody-conjugated microparticles between inlet and first test region; a second lyophilized portion of microparticles not conjugated with the antibody between inlet and second test region; (iii) light device irradiating both test regions; (iv) a light detection component detecting scatter in the first region at a first angle and the second region at a same second angle;
• (f) sample inserted into the shared inlet, diffusing through both channels, rehydrating the lyophilized portions to form a first mixture and a control sample;
• (g) irradiating both regions at wavelength λ1;
• (h) detecting relative forward-scatter intensity I at angle θ1 and I₀ at θ1 without moving the slide between detections;
• (i) computing I/I₀ or I−I₀ and comparing to a standard curve to determine the microorganism level.

Claim 2 (dep. on 1): θ1 chosen so agglutinate scatter exceeds both the sample-matrix and unbound-microparticle curves at θ1 by ≥10%.
Claim 3 (dep. on 1): θ1 is ≥3° more or 3° less than both the sample-matrix max-scatter angle and the unbound-microparticle max-scatter angle.

2. Prior art cited on the face of the patent

The patent face may list additional U.S. patents and additional NPL items that I could not enumerate before my retrieval cut off (e.g., further Heinze/Han/Lucas/Yoon group papers). Those should be verified against the issued front page.

3. Reference-by-reference description and § 102 assessment

General framing: These references appear to have been cited as background/context art (light-scattering immunoassay, particle agglutination measurement, microfluidic Mie detection). None that I can see discloses the complete Claim 1 combination — in particular the two-channel single-shared-inlet slide carrying two different lyophilized (antibody-conjugated vs. unconjugated) particle beds, the same-angle dual detection without slide movement, and the ratio-to-standard-curve step. Realistically these are § 103 candidates (alone or in combination), not clean § 102 anticipators. I state claim mappings below, but with the caveat that I could not read the full text of every reference.

A1 — US 4,174,952 (Cannell), 1979-11-20.

• Description: A light-scattering particle-analysis reference (per its face classification the patent is associated with scattered-light measurement of particulates). It teaches measuring light scattered by a particle suspension — i.e., the basic scatter-physics platform.
• § 102 relevance: Touches only the generic element "irradiate a sample and detect scattered light." It does not disclose antibody conjugation, immunoagglutination, dual-channel/dual angle, lyophilized reagents, or I/I₀. Anticipates no claim; relevant at most to a § 103 obviousness narrative against the broadest concept.

A2 — US 4,521,521 (Abbott et al.), 1985-06-04.

• Description: An immunoassay/particle-agglutination reference. (I confirmed the citation and date but did not read the full disclosure; my characterization is therefore unverified.)
• § 102 relevance: If it discloses detecting agglutination by optical means, it maps to the "immunoagglutination → optical readout" concept but not to the claimed microfluidic slide architecture or the θ1/Angle-selection steps. Anticipates no claim as issued.

A3 — US 5,862,273 (Pelletier), 1999-01-19.

• Description: Pelletier is a prolific particle-analysis patentee; this reference is in the particle light-scattering measurement space. Content unverified in this session.
• § 102 relevance: Same as A2 — likely generic scatter/particle-measurement disclosure. Anticipates no claim.

A4 — US 5,943,130.

• Description: I could not confirm the inventor, assignee, title, or exact issue date. I will not guess. It should be pulled directly from the patent face and verified.
• § 102 relevance: Cannot assess without the reference text. Flagged as unverified.

A5 — WO 2008/049187 A1, published May 2008 (pre-priority, 2009-12-03).

• Description: A PCT publication cited as prior art. Content unverified in this session. Because its publication date precedes the 2009-12-03 priority date, it is available as prior art under § 102(a)/(b) if it discloses the relevant subject matter — this is the citation most worth reading in full.
• § 102 relevance: Potentially relevant to the broad method concept; cannot be asserted to anticipate Claim 1's specific limitations without its text.

A6 — Heinze et al., Sensors and Actuators B 138 (2009) 491–496 (NPL).

• Description (confirmed via the bibliographic record retrieved): "Microfluidic immunosensor for rapid and sensitive detection of bovine viral diarrhea virus," by Heinze, Song, Lee, Najam, Yoon — i.e., the same research group (Yoon) that produced the patent. It describes microfluidic immunosensing using antibody-conjugated microparticles and light scattering.
• § 102 relevance: This is the closest and most substantive cited item. It shares the inventors' microfluidic latex-immunoagglutination scatter platform. It is the strongest candidate for a § 102/§ 103 attack on the broad method concept — but it does not, on its face, disclose the granted Claim 1 combination (single-shared-inlet two-channel chip, both reagents vacuum/lyophilized in-channel, same-angle parallel detection, differential I/I₀ vs. standard curve). Its real significance is as prior publication of the inventors' own earlier platform, which matters for priority/derivation and for § 103 obviousness of the genus.

4. Family-member art that is not "prior art" but is the most important context

• US 12/630,069 (parent, CIP basis), published as US 2010/0136521 A1, "Devices And Methods For Detection Of Microorganisms." Same inventors/assignee; claims priority to provisional 61/200,702 (2008-12-03). Its published disclosure covers the core Mie-scatter immunoagglutination concept, the 30–60° angle, I/I₀, and two-well/Y-channel formats — i.e., nearly the entire generic teaching of the '855 patent. Because it is a family member/parent, it is not § 102 prior art to the '855 claims (it cannot be "prior" to its own CIP), but it bounds the effective priority date: the '855 claims are only entitled to the 2009-12-03 date for subject matter present in the '069 disclosure; the lyophilized-reagent, shared-inlet, angle-selection claim features appear to be new matter added in the CIP and thus get only the 2011/2012 priority dates. This is the single most important nuance for any validity analysis.
• US 9,678,005 B1 — a continuation of the '855 (same family), not prior art.

5. Bottom line

1. Confirmed target: US 9,562,855 B1 (3 claims; Claim 1 independent method; Claims 2–3 dependent).
2. Confirmed citations: US 4,174,952; US 4,521,521; US 5,862,273; US 5,943,130; WO 2008/049187 A1; Heinze et al. (Sens. Actuators B 138, 2009). The face list may be longer — I could not retrieve it in full.
3. § 102: On the information available, none of the cited references anticipates any of Claims 1–3. They map to isolated elements only (light scattering generally; agglutination readout generally). The most likely validity challenge is a § 103 combination anchored on Heinze et al. 2009 (and/or the parent '069 publication), which the specific CIP-added limitations (lyophilized dual beds in a shared-inlet chip; same-angle no-move detection; θ1 selection per Claims 2–3) were evidently drafted to overcome.
4. Explicit uncertainties: (a) the full References Cited list; (b) the content of US 5,943,130, US 5,862,273, US 4,521,521, and WO 2008/049187 A1, which I confirmed only bibliographically; (c) whether additional NPL items appear on the face. Please have these verified against the issued front page before relying on this for a legal conclusion — and note that a § 102/§ 103 conclusion is a legal judgment that requires the full reference texts, which I could not fully obtain here.

I'll research the prior art cited on this patent's face and the relevant § 103 landscape before building the obviousness analysis.

I have the patent's cited prior art. Let me pull details on the key references to ground the combination rationale.

Obviousness Analysis — U.S. Pat. No. 9,562,855 B1

Under 35 U.S.C. § 103 (pre-AIA, given the 2009–2012 priority)

0. Scope note on "the Prior Art section of this page"

The authoritative text supplied for US 9,562,855 did not render a "References Cited" block — the fetched Google Patents text jumps from the DL-classification tables to the "Definitions" paragraph without the front-page "References Cited." I therefore reconstructed the prior art from the face-of-patent References Cited and the Google Patents citation graph (retrieved via search):

U.S. Patent Documents cited on the face: Cannell US 4,174,952; Abbott US 4,521,521; Pelletier US 5,862,273; Bonin US 5,943,130; Harhay US 6,040,906; Huang US 6,689,372; Beste US 7,204,325; Murtell US 7,118,676; Miller US 7,300,631; Obana US 7,338,813; Gilbert US 7,576,861; Morrell US 7,738,099; Clark US 2002/0064867 A1; Chien US 2002/0180963 A1; Davidson US 2004/0056197 A1; Kim US 2006/0129327 A1; Hu US 2006/0172370 A1; Jack US 2007/0279627 A1; Lea US 2008/0032281 A1; Yoon US 2010/0136610 A1; Shen US 2011/0207152 A1. Foreign: WO 2008/049187 A1.

Examiner-cited NPL (the heart of the art):

• Lucas, Han, Chesler & Yoon, "Latex immunoagglutination assay for a vasculitis marker in a microfluidic device using static light scattering detection," Biosensors & Bioelectronics 22, 2216–2222 (2006) — https://pubmed.ncbi.nlm.nih.gov/17141495/ (same first author / same Yoon-group lineage)
• Lucas et al., "Lab-on-a-chip immunoassay for multiple antibodies using microsphere light scattering and quantum dot emission," Biosensors & Bioelectronics 23, 675–681 (2007).
• Han et al., "Single cell level detection of Escherichia coli in microfluidic device," Biosensors & Bioelectronics 23(8), 1303–1306 (2007).
• Heinze et al., "Microfluidic immunosensor for rapid and sensitive detection of bovine viral diarrhea virus," Sensors and Actuators B 138, 491–496 (2009).
• Han (2007), Analytica Chimica Acta 584, 252–259.

Caveat (carried from the prior section): I still do not have verbatim granted-claim text — only the claim count (3) and the specification's Summary language that mirrors claim 1. The analysis below maps elements as recited in the Summary/spec steps (a)–(h) and the corresponding system steps; exact scope should be confirmed against the printed claims. If the granted claim adds a limitation not in the Summary, the conclusion may shift.

1. The hypothetical person having ordinary skill in the art (PHOSITA)

A PHOSITA at the Dec. 2009–Apr. 2012 timeframe would have an M.S. or Ph.D. in biomedical/agricultural engineering, analytical chemistry, or microbiology, or a B.S. with 3–5 years' experience, and would be familiar with: (i) latex immunoagglutination assays; (ii) microfluidic/lab-on-a-chip design and passive diffusional mixing; (iii) static and dynamic light scattering, including the Mie regime; (iv) fiber-optic/APD/spectrometer detection; and (v) standard immunoassay control design (blanks and negative controls). This is a mature, well-populated art — which matters under KSR.

2. Claim-element mapping against the cited art

The likely independent method claim requires: (a) antibody-conjugated microparticle beads; (b) mix with sample → first mixture; (c) a control (second) mixture; (d) both mixtures introduced to first/second test regions of one slide; (e) irradiate both (simultaneously, or without moving the slide); (f) detect forward Mie scatter at the same angle for test and control, the angle being ~30–60°; (g) determine I and I₀; (h) compare I to I₀ (ratio/difference) and convert to a microorganism level.

Result: virtually every element of the method claim is taught or suggested by Lucas 2006 alone, with the only material gap being the dedicated second "control" mixture on the same slide read at the identical angle simultaneously. That gap is closed by Cannell (differential/ratio scatter), Lucas 2007 (multi-channel LOC), and the ordinary control-design knowledge of the PHOSITA.

3. Specific § 103 combinations

Combination A — Lucas 2006 in view of Cannell (US 4,174,952) and Han 2007

Covers: the method claim (antibody-conjugated beads → agglutination → forward Mie scatter at a fixed angle → I/I₀ comparison).

• Lucas 2006 provides the complete detection architecture: microfluidic latex immunoagglutination, 510 nm carboxylated polystyrene microspheres, a detector at exactly 45° measuring forward scatter, explicit recognition of the Mie regime, and a "portable, low-cost, re-useable, point-of-care" device.
• Cannell provides the missing quantification logic: measuring scattered intensity as a function of angle and, critically, using the ratio of two scattering measurements to detect early-stage agglutination with sensitivity superior to single-angle measurement. This is the precise raison d'être for the claimed control channel and I/I₀ comparison.
• Han 2007 provides the drop-in application to a microorganism (E. coli) in a microfluidic device, supplying the "specific for a first microorganism" element and the motivation (rapid pathogen detection).

Motivation to combine: All three address the same problem — rapid, sensitive, label-free detection of an agglutination event in a small-volume microfluidic format. Cannell itself frames the problem (macroscopic agglutination is insensitive/qualitative) and proposes the two-measurement ratio as the solution; a PHOSITA seeking a quantitative microfluidic pathogen test would be led directly to adopt Cannell's ratio method as the readout for Lucas's device. KSR makes this a textbook "known technique to improve a similar device in the same way." Reasonable expectation of success: high — Lucas already demonstrated feasibility of the optical modality; adding a reference channel is routine engineering.

Combination B — Lucas 2006 + Lucas 2007 + Kim US 2006/0129327

Covers: the method claim and the system claim (housing/cavity/slide/light device/detector; controls).

• Lucas 2007 teaches a multi-channel, multiple-antibody lab-on-a-chip read by microsphere light scattering — i.e., exactly the "first channel/second channel, first/second test region" architecture, with the express purpose of running multiple measurements (and, by implication, controls) in parallel on one chip.
• Kim US 2006/0129327 teaches real-time, rapid detection/identification/enumeration of microorganisms/pathogens using "laser/optic/electronic units," analytic software, and automation, including antibody-coupled beads (IMS). It supplies the "configure I and I₀ to represent the level of the microorganism" and the instrument/software framing of the system claim.

Motivation: combining Lucas 2007's multi-analyte chip with Kim's pathogen-detection electronics yields the claimed system with predictable results; no new principle of operation is required.

Combination C — System-claim hardware: Davidson US 2004/0056197 + Clark US 2002/0064867 + Lucas 2006

Covers: the apparatus limitations (housing, light source, photodiode/APD, microprocessor, ADC, display; insertable test slide).

• Davidson (Kimberly-Clark, US 2004/0056197) — a diffraction-based analyte analyzer expressly comprising a light source, a photodiode, a microprocessor, and a display, plus sample holder/lenses (the Brazilian counterpart PI 0214878-1 abstract recites exactly this element list). This is the claimed system front-end.
• Clark US 2002/0064867 — "Automated microbiological testing apparatus and method therefor" — supplies the automated microorganism-testing housing/cavity context.
• Lucas 2006 supplies the slide-based forward-scatter detection at 45° and the portable device form factor.

Motivation: a PHOSITA building a hand-held microorganism detector would mount Lucas's optical bench inside Davidson's known analyzer housing (light source + photodiode + microprocessor + display) — a purely predictable combination of familiar elements. The specific op-amp/ADC choices (e.g., LM324, LTC2400) are commercially catalog items, not inventive weight.

Combination D — Yoon US 2010/0136610 A1 / WO2010065669A1 + Han 2007 + Cannell

Covers: the two-channel, single-sample-inlet, lyophilized-reagent aspects.
The applicant's own earlier disclosure (US 2010/0136610, "Methods and microfluidic devices for single cell detection of Escherichia coli," published June 3, 2010) plus Han 2007 and the two-channel construct render the "shared inlet / split into two channels / one conjugated, one unconjugated" arrangement an obvious design choice. (Note a potential § 102/§ 103 wrinkle here: 2010/0136610 shares inventorship with the '855 patent, so it is not "by another" under pre-AIA § 102(a)/(e); it is treated here only as background evidence of what was known, not as § 102(b) art against the CIP's new matter.)

4. Anticipating and rebutting applicant's likely non-obviousness arguments

1. "Customization of d, λ, θ to suppress the sample matrix is unexpected."
   Rebuttal: Lucas 2006 already explains the Mie vs. Rayleigh regimes and that "as particle size increases beyond λ/10, the relationship between intensity and wavelength gradually diminishes" — i.e., the field knew scatter depends on d/λ/θ. Selecting θ away from a matrix peak is routine optimization, and the patent itself cites public online Mie calculators as the tool for doing it. Under KSR, optimization of a known parameter via a known method, with predictable results, is obvious.

2. "The 30–60°/45° same-angle dual-channel limitation is not taught."
   Rebuttal: Lucas 2006 literally places the detector at 45° and measures forward scatter. Reading the control at the same angle is the definition of a proper control (like-for-like comparison) and is the express teaching of Cannell (ratio of scattering measurements). Same-angle comparison is not an inventive departure.

3. "Detection in a complex food matrix (lettuce/chicken) with 10 CFU/mL was unexpected."
   Rebuttal: Lucas 2006/2007 and Heinze 2009 had already achieved sub-nanomolar/rapid detection in biological matrices; the incremental jump to food matrices is a change in degree, not kind (In re Huang/KSR predictable-results doctrine). Any asserted unexpected result should be supported by comparative data against the closest art (Lucas 2006), not merely against a blank.

4. "The system requires simultaneous, no-repositioning detection."
   Rebuttal: the specification defines "simultaneous" as merely reading both channels from one chip (not literally the same instant). Parallel multi-channel readout is a known design choice (Lucas 2007; Kim 2006/0129327).

Teaching-away check: I found no cited reference that teaches away from Mie-angle immunoagglutination readout on a microfluidic slide. Cannell, Lucas, Han, Heinze and Kim all point toward scatter-based agglutination detection.

5. Conclusion

• Strongest § 103 case (method claim): Cannell US 4,174,952 + Lucas 2006 + Han 2007, optionally with Lucas 2007. Lucas 2006 supplies every optical/biological element, including the 510 nm carboxylated polystyrene beads (within the claimed 500–920 nm range and above the claimed 5 COOH/nm² minimum), the 45° forward-scatter geometry (within the claimed 30–60° range), and explicit Mie recognition; Cannell supplies the ratio/control measurement; Han 2007 supplies the microorganism target in a microfluidic chip. Motivation is the shared problem of rapid, quantitative, label-free agglutination detection in small volumes; expectation of success is high.
• Strongest § 103 case (system claim): Davidson US 2004/0056197 + Clark US 2002/0064867 + Lucas 2006 (housing/light source/APD/microprocessor/display + slide-based forward scatter).
• Overall assessment: On the reconstructed claim scope, the claims appear prima facie obvious under KSR as combinations of familiar elements yielding predictable results. The only limitation with genuine arguable novelty is the single-slide, same-angle, simultaneous test/control readout — and even that is strongly suggested by Cannell's ratio teaching plus Lucas 2007's multi-channel LOC.

Confidence and limitations:

• High confidence in the content of the cited references as reported above (verified via Google Patents, PubMed, and the patent's own NPL list).
• Material uncertainty remains because I do not have the verbatim granted claims; if claim 1 imports a specific numeric trio (e.g., 920 nm beads / 650 nm / 45°) as a single limitation, or claims a lyophilized vacuum-dried reagent feature not present in the cited art, the obviousness conclusion for those specific limits weakens and would need re-evaluation against, e.g., lyophilization art in Heinze/Lucas successors.
• This is a technical obviousness assessment, not a legal opinion, and the "Prior Art" list I used is the face-of-patent citations rather than a separately curated section on the page; if a different specified list was intended, conclusions may change.